-
-
-
-
-
-
-
Regenxbio Inc. (RGNX) PT Raised to $18 at Leerink
-
-
-
-
-
-
-
Regenxbio (RGNX) Misses Q1 EPS by 38c, Misses on Revenue
-
-
-
-
-
-
-
Regenxbio Inc. (RGNX) PT Lowered to $17 at Morgan Stanley
-
-
-
-
-
-
-
REGENXBIO receives FDA rejection letter for gene therapy RGX-121
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
-
-
-
-
-
-
-
REGENXBIO completes pivotal trial enrollment for duchenne gene therapy
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX)
-
430,619 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

